Allarity Therapeutics, Inc. has officially requested the withdrawal of its registration statement on Form S-1, initially filed on October 30, 2023, with the U.S. Securities and Exchange Commission (SEC). The company decided not to proceed with the public offering that the registration was meant to facilitate. The registration statement had not been declared effective by the SEC, and no securities were sold under it. Allarity Therapeutics cited the withdrawal as being in the public interest and protective of investors. The company also requested that the SEC credit the fees paid for the withdrawn registration to be used against future filings. The request for withdrawal was signed by Chief Executive Officer Thomas H. Jensen and addressed to the SEC's Division of Corporation Finance, Office of Life Sciences.

Allarity Therapeutics, Inc. has officially requested the withdrawal of its registration statement on Form S-1, initially filed on October 30, 2023, with the U.S. Securities and Exchange Commission (SEC). The company decided not to proceed with the public offering that the registration was meant to facilitate. The registration statement had not been declared effective by the SEC, and no securities were sold under it. Allarity Therapeutics cited the withdrawal as being in the public interest and protective of investors. The company also requested that the SEC credit the fees paid for the withdrawn registration to be used against future filings. The request for withdrawal was signed by Chief Executive Officer Thomas H. Jensen and addressed to the SEC's Division of Corporation Finance, Office of Life Sciences.